<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="98989">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01706458</url>
  </required_header>
  <id_info>
    <org_study_id>CO11816</org_study_id>
    <nct_id>NCT01706458</nct_id>
  </id_info>
  <brief_title>Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate Cancer</brief_title>
  <official_title>Pilot Trial of Sipuleucel-T, With or Without pTVG-HP DNA Booster Vaccine, in Patients With Castrate-Resistant, Metastatic Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dendreon</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Data and Safety Monitoring Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to try to enhance subjects' own immune response against
      prostate cancer.  In this study the investigators will be testing the effectiveness of
      adding pTVG-HP vaccine with Sipuleucel-T (Provenge).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Measure immune responses following treatment with sipuleucel-T</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to radiographic disease progression</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure prostate-specific antigen (PSA) doubling time</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Overall Survival</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Number of Circulating Tumor Cells</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>PAP-specific antibody and T-cell immune responses following treatment with sipuleucel-T and DNA vaccine will be summarized in tabular format.</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Logistic regression analysis will be conducted to evaluate whether PAP-specific immune response is associated with prolonged (1-year) progression-free survival.</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Logistic regression analysis will be conducted to evaluate whether baseline immune responses predict for immune responses elicited/augmented following treatment with sipuleucel-T +/- DNA vaccine.</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>The detection of antigen spread to other prostate associated antigens, and the identification of specific antigens recognized, will be analyzed descriptively.</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>sipuleucel-T</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sipuleucel-T will be administered intravenously per standard of care biweekly, weeks 0, 2, and 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sipuleucel-T with DNA Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sipuleucel-T will be administered intravenously per standard of care biweekly, weeks 0, 2, and 4.
Then, DNA vaccine (pTVG-HP (100 µg) with rhGM-CSF (208 µg)) will be administered intradermally biweekly (weeks 6, 8, 10, 12), then every 3 months (months 6 and 9) to complete a 1-year treatment period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sipuleucel-T</intervention_name>
    <arm_group_label>sipuleucel-T</arm_group_label>
    <other_name>Provenge</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DNA Vaccine</intervention_name>
    <arm_group_label>sipuleucel-T with DNA Vaccine</arm_group_label>
    <other_name>pTVG-HP with rhGM-CSF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Prostate Cancer

          -  Castrate Resistant Disease

          -  Progressive disease despite androgen deprivation therapy as defined by rising PSA
             levels or progressive soft tissue or bony disease

          -  Normal organ function per laboratory tests

          -  Life expectancy of at least 6 months

        Exclusion Criteria:

          -  History of life-threatening autoimmune disease

          -  Small cell or other variant prostate cancer histology

          -  Serum testosterone at screening &lt; 50 ng/dL

          -  Prior cytotoxic chemotherapy within 6 months of registration

          -  Patients who have undergone splenectomy

          -  Radiation therapy within 4 weeks of registration is prohibited, or anticipated need
             for radiation therapy (e.g. imminent pathological fracture or spinal cord
             compression) within 3 months of registration.

          -  Another malignancy other than non-melanoma skin cancer or carcinoma in situ of the
             bladder.  Subjects with a history of other curatively treated cancers are eligible.

          -  Known brain metastases

          -  Any antibiotic therapy or evidence of infection within 1 week of registration
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Douglas McNeel, M.D., PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Glenn Liu, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cancer Connect</last_name>
    <phone>800-622-8922</phone>
    <email>cancerconnect@uwcarbone.wisc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Wisconsin Carbone Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Douglas McNeel, M.D., PhD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.uwhealth.org/uw-carbone-cancer-center/cancer/10252</url>
    <description>University of Wisconsin Carbone Cancer Center</description>
  </link>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 10, 2013</lastchanged_date>
  <firstreceived_date>October 9, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Wisconsin, Madison</investigator_affiliation>
    <investigator_full_name>Douglas McNeel</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>Vaccine</keyword>
  <keyword>pTVG-HP</keyword>
  <keyword>Prostate Cancer</keyword>
  <keyword>Castrate Resistant</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
